BidaskClub upgraded shares of Uniqure (NASDAQ:QURE) from a sell rating to a hold rating in a report issued on Friday.
QURE has been the subject of a number of other reports. Zacks Investment Research downgraded shares of Uniqure from a strong-buy rating to a hold rating in a research report on Wednesday, July 25th. Cantor Fitzgerald initiated coverage on shares of Uniqure in a research note on Thursday, July 26th. They issued an overweight rating and a $58.00 price objective on the stock. Janney Montgomery Scott reissued a buy rating on shares of Uniqure in a research note on Wednesday, August 8th. HC Wainwright set a $42.00 price objective on shares of Uniqure and gave the company a buy rating in a research note on Thursday, August 23rd. Finally, Chardan Capital reissued a buy rating and issued a $50.00 price objective on shares of Uniqure in a research note on Thursday, October 18th. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Buy and an average price target of $44.90.
NASDAQ QURE opened at $26.36 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.36 and a quick ratio of 8.36. Uniqure has a 1-year low of $13.71 and a 1-year high of $43.23. The company has a market capitalization of $993.90 million, a PE ratio of -8.97 and a beta of 0.27.
Uniqure (NASDAQ:QURE) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.04. Uniqure had a negative net margin of 677.98% and a negative return on equity of 72.12%. The company had revenue of $3.05 million during the quarter, compared to the consensus estimate of $3.37 million. On average, sell-side analysts anticipate that Uniqure will post -2.44 earnings per share for the current year.
A number of large investors have recently made changes to their positions in the stock. Northern Trust Corp bought a new position in Uniqure in the second quarter valued at approximately $602,000. FMR LLC increased its stake in Uniqure by 16.6% in the second quarter. FMR LLC now owns 3,694,681 shares of the biotechnology company’s stock valued at $139,659,000 after acquiring an additional 526,283 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Uniqure in the second quarter valued at approximately $628,000. California Public Employees Retirement System increased its stake in Uniqure by 101.3% in the second quarter. California Public Employees Retirement System now owns 28,427 shares of the biotechnology company’s stock valued at $1,075,000 after acquiring an additional 14,307 shares during the last quarter. Finally, Redmile Group LLC bought a new stake in shares of Uniqure during the second quarter worth $61,402,000. 59.08% of the stock is currently owned by institutional investors and hedge funds.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Featured Story: Risk Tolerance
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.